Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy.
antiproliferation
antitumor agents
gene technology
hemolytic toxicity
prodrugs
Journal
Chemistry (Weinheim an der Bergstrasse, Germany)
ISSN: 1521-3765
Titre abrégé: Chemistry
Pays: Germany
ID NLM: 9513783
Informations de publication
Date de publication:
05 Dec 2019
05 Dec 2019
Historique:
received:
30
08
2019
revised:
23
09
2019
pubmed:
25
9
2019
medline:
1
2
2020
entrez:
25
9
2019
Statut:
ppublish
Résumé
Sixteen cationic prodrugs of the antitumor alkylphospholipid (APL) erufosine were rationally synthesized to provide original gene delivery reagents with improved cytotoxicity profile. The DNA complexation properties of these cationic lipids were determined and associated transfection rates were measured. Furthermore, the self-assembly properties of the pro-erufosine compounds were investigated and their critical aggregation concentration was determined. Their hydrolytic stability under pH conditions mimicking the extracellular environment and the late endosome milieu was measured. Hemolytic activity and cytotoxicity of the compounds were investigated. The results obtained in various cell lines demonstrate that the prodrugs of erufosine display antineoplastic activity similar to that of the parent antitumor drug but are not associated with hemolytic toxicity, which is a dose-limiting side effect of APLs and a major obstacle to their use in anticancer therapeutic regimen. Furthermore, by using lipoplexes prepared from a prodrug of erufosine and a plasmid DNA encoding a pro-apoptotic protein (TRAIL), evidence was provided for selective cytotoxicity towards tumor cells while nontumor cells were resistant. This study demonstrates that the combination approach involving well tolerated erufosine cationic prodrugs and cancer gene therapy holds significant promise in tumor therapy.
Identifiants
pubmed: 31549752
doi: 10.1002/chem.201903976
doi:
Substances chimiques
Antineoplastic Agents
0
Cations
0
Indicators and Reagents
0
Organophosphates
0
Prodrugs
0
Quaternary Ammonium Compounds
0
erucylphospho-N,N,N-trimethylpropylammonium
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15662-15679Subventions
Organisme : Labex Medalis
ID : 482
Organisme : Conseil Régional d'Alsace
ID : 482
Organisme : Alsace contre le Cancer
ID : 2019-002
Informations de copyright
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
J. de Almeida Pachioni, J. G. Magalhães, E. J. C. Lima, L. de Moura Bueno, J. F. Barbosa, M. M. de Sá, C. O. Rangel-Yagui, J. Pharm. Pharm. Sci. 2013, 16, 742-759;
P.-A. Jaffrès, C. Gajate, A. M. Bouchet, H. Couthon-Gourvès, A. Chantôme, M. Potier-Cartereau, P. Besson, P. Bougnoux, F. Mollinedo, C. Vandier, Pharmacol. Ther. 2016, 165, 114-131;
P. Ríos-Marco, C. Marco, X. Gálvez, J. M. Jiménez-López, M. P. Carrasco, Biochim. Biophys. Acta- Biomembr. 2017, 1859, 1657-1667.
A. Kostadinova, T. Topouzova-Hristova, A. Momchilova, R. Tzoneva, M. R. Berger, Adv. Prot. Chem. Struct. Biol. 2015, 101, 27-66, edited by R. Donev.
H. Eibl, D. Arnold, H. U. Weltzien, O. Westphal, Liebigs Ann. Chem. 1967, 709, 226-230.
C. Gajate, F. Mollinedo, Curr. Drug Metab. 2002, 3, 491-525.
R. Andreesen, M. Modolell, H. U. Weltzien, H. Eibl, H. H. Common, G. W. Löhr, P. G. Munder, Cancer Res. 1978, 38, 3894-3899;
P. G. Munder, M. Modolell, R. Andreesen, H. U. Weltzien, O. Westphal, Springer Semin. Immunopathol. 1979, 2, 187-203.
D. Berkovic, Gen. Pharmacol. 1998, 31, 511-517.
P. Hilgard, T. Klenner, J. Stekar, G. Nössner, B. Kutscher, J. Engel, Eur. J. Cancer 1997, 33, 442-446.
S. R. Vink, J. H. M. Schellens, W. J. van Blitterswijk, M. Verheij, Invest. New Drugs 2005, 23, 279-286.
P. G. Richardson, C. Eng, J. Kolesar, T. Hideshima, K. C. Anderson, Expert Opin. Drug Metab. Toxicol. 2012, 8, 623-633.
J. Kötting, M. R. Berger, C. Unger, H. Eibl, Cancer Chemother. Pharmacol. 1992, 30, 105-112.
R. G. Bagley, L. Kurtzberg, C. Rouleau, M. Yao, B. A. Teicher, Cancer Chemother. Pharmacol. 2011, 68, 1537-1546.
J. C. Bendell, J. Nemunaitis, S. J. Vukelja, C. Hagenstad, L. T. Campos, R. C. Hermann, P. Sportelli, L. Gardner, D. A. Richards, J. Clin. Oncol. 2011, 29, 4394-4400;
S. Fu, B. T. Hennessy, C. S. Ng, Z. Ju, K. R. Coombes, J. K. Wolf, A. K. Sood, C. F. Levenback, R. L. Coleman, J. J. Kavanagh, D. M. Gershenson, M. Markman, K. Dice, A. Howard, J. Li, Y. Li, K. Stemke-Hale, M. Dyer, E. Atkinson, E. Jackson, V. Kundra, R. Kurzrock, R. C. Bast, G. B. Mills, Gynecol. Oncol. 2012, 126, 47-53;
I. Gojo, A. Perl, S. Luger, M. R. Baer, K. J. Norsworthy, K. S. Bauer, M. Tidwell, S. Fleckinger, M. Carroll, E. A. Sausville, Invest. New Drugs 2013, 31, 1217-1227;
A. Guidetti, C. Carlo-Stella, S. L. Locatelli, W. Malorni, R. Mortarini, S. Viviani, D. Russo, A. Marchianò, R. Sorasio, A. Dodero, L. Farina, L. Giordano, M. Di Nicola, A. Anichini, P. Corradini, A. M. Gianni, Clin. Cancer Res. 2014, 20, 5641-5651;
P. G. Richardson, J. Wolf, A. Jakubowiak, J. Zonder, S. Lonial, D. Irwin, J. Densmore, A. Krishnan, N. Raje, M. Bar, T. Martin, R. Schlossman, I. M. Ghobrial, N. Munshi, J. Laubach, J. Allerton, T. Hideshima, K. Colson, E. Poradosu, L. Gardner, P. Sportelli, K. C. Anderson, J. Clin. Oncol. 2011, 29, 4243-4249.
C. Belka, V. Jendrossek, M. Pruschy, S. Vink, M. Verheij, W. Budach, Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 542-554;
S. R. Vink, W. J. van Blitterswijk, J. H. M. Schellens, M. Verheij, Cancer Treat. Rev. 2007, 33, 191-202.
R. Zeisig, A. Ress, I. Fichtner, W. Walther, Cancer Gene Ther. 2003, 10, 302-311.
N. Settelen, O. Roch, D. Bock, R. Rooke, S. Braun, O. Meyer, J. Controlled Release 2004, 94, 237-244.
H. A. Elrod, Y.-D. Lin, P. Yue, X. Wang, S. Lonial, F. R. Khuri, S.-Y. Sun, Mol. Cancer Ther. 2007, 6, 2029-2038.
Z. U. Rehman, I. S. Zuhorn, D. Hoekstra, J. Controlled Release 2013, 166, 46-56.
S. Mukherjee, T. T. Soe, F. R. Maxfield, J. Cell Biol. 1999, 144, 1271-1284.
R. L. Juliano, Nucl. Acid Ther. 2018, 28, 166.
B. Gaillard, J.-S. Remy, F. Pons, L. Lebeau, unpublished results.
M. C. Georgieva, S. M. Konstantinov, M. Topashka-Ancheva, M. R. Berger, Cancer Lett. 2002, 182, 163-174.
P. Pierrat, A. Casset, P. Didier, D. Kereselidze, M. Lux, F. Pons, L. Lebeau, ChemBioChem 2016, 17, 1771-1783;
P. Pierrat, A. Casset, D. Kereselidze, M. Lux, F. Pons, L. Lebeau, Macromol. Biosci. 2016, 16, 984-989;
P. Pierrat, G. Creusat, G. Laverny, F. Pons, G. Zuber, L. Lebeau, Chem. Eur. J. 2012, 18, 3835-3839;
P. Pierrat, D. Kereselidze, M. Lux, L. Lebeau, F. Pons, Int. J. Pharm. 2016, 511, 205-218;
P. Pierrat, D. Kereselidze, P. Wehrung, G. Zuber, F. Pons, L. Lebeau, Pharm. Res. 2013, 30, 1362-1379;
P. Pierrat, G. Laverny, G. Creusat, P. Wehrung, J.-M. Strub, A. VanDorsselaer, F. Pons, G. Zuber, L. Lebeau, Chem. Eur. J. 2013, 19, 2344-2355.
P. Gentine, A. Bubel, C. Crucifix, L. Bourel-Bonnet, B. Frisch, J. Liposome Res. 2012, 22, 18-30.
N. Dan, D. Danino, Adv. Colloid Interface Sci. 2014, 205, 230-239.
I. S. Zuhorn, U. Bakowsky, E. Polushkin, W. H. Visser, M. C. A. Stuart, J. Engberts, D. Hoekstra, Mol. Ther. 2005, 11, 801-810.
J. Rejman, V. Oberle, I. S. Zuhorn, D. Hoekstra, Biochem. J. 2004, 377, 159-169.
S. Audouy, G. Molema, L. de Leij, D. Hoekstra, J. Gene Med. 2000, 2, 465-476.
S. E. Han, H. Kang, G. Y. Shim, M. S. Suh, S. J. Kim, J. S. Kim, Y. K. Oh, Int. J. Pharm. 2008, 353, 260-269.
C. L. Chan, K. K. Ewert, R. N. Majzoub, Y. K. Hwu, K. S. Liang, C. Leal, C. R. Safinya, J. Gene Med. 2014, 16, 84-96;
O. Zelphati, L. S. Uyechi, L. G. Barron, F. C. Szoka, Biochim. Biophys. Acta Lipids Lipid Metab. 1998, 1390, 119-133;
L. Li, H. M. Song, K. Luo, B. He, Y. Nie, Y. Yang, Y. Wu, Z. W. Gu, Int. J. Pharm. 2011, 408, 183-190.
J. Kötting, N. W. Marschner, W. Neumuller, C. Unger, H. Eibl, Prog. Exp. Tumor Res. 1992, 34, 131-142;
E. A. M. Fleer, D. Berkovic, C. Unger, H. Eibl, Prog. Exp. Tumor Res. 1992, 34, 33-46.
M. C. Parlato, J. P. Jee, M. Teshite, S. Mecozzi, J. Org. Chem. 2011, 76, 6584-6591.
H. Eibl, P. Kaufmann-Kolle, J. Liposome Res. 1995, 5, 131-148;
F. Schuettauf, K. H. Eibl, S. Thaler, K. Shinoda, R. Rejdak, C. A. May, G. Blatsios, U. Welge-Lussen, Curr. Eye Res. 2005, 30, 813-820.
M. Lukac, M. Mrva, M. Garajova, G. Mojzisova, L. Varinska, J. Mojzis, M. Sabol, J. Kubincova, H. Haragova, F. Ondriska, F. Devinsky, Eur. J. Med. Chem. 2013, 66, 46-55.
I. Fichtner, R. Zeisig, H. Naundorf, S. Jungmann, D. Arndt, G. Asongwe, J. A. Double, M. C. Bibby, Breast Cancer Res. Treat. 1994, 32, 269-279;
P. Kaufmann-Kolle, J. Drevs, M. R. Berger, J. Kotting, N. Marschner, C. Unger, H. Eibl, Cancer Chemother. Pharmacol. 1994, 34, 393-398.
R. Zeisig, S. Jungmann, D. Arndt, A. Schutt, E. Nissen, Anti-Cancer Drugs 1993, 4, 57-64.
T. Mosmann, J. Immunol. Methods 1983, 65, 55-63.
J. M. W. Gee, A. Howell, W. J. Gullick, C. C. Benz, R. L. Sutherland, R. J. Santen, L. A. Martin, F. Ciardiello, W. R. Miller, M. Dowsett, P. Barrett-Lee, J. F. R. Robertson, S. R. Johnston, H. E. Jones, A. E. Wakeling, R. Duncan, R. I. Nicholson, Endocr.-Relat. Cancer 2005, 12, S1-S7.
H. J. Lee, G. L. Zhuang, Y. Cao, P. Du, H. J. Kim, J. Settleman, Cancer Cell 2014, 26, 207-221.
W. Huang, L. Q. Chen, L. Kang, M. J. Jin, P. Sun, X. Xin, Z. G. Gao, Y. H. Bae, Adv. Drug Delivery Rev. 2017, 115, 82-97.
V. Tsouris, M. K. Joo, S. H. Kim, I. C. Kwon, Y. Y. Won, Biotechnol. Adv. 2014, 32, 1037-1050.
Y. S. Shi, X. Pang, J. Q. Wang, G. Liu, Adv. Healthcare Mater. 2018, 7, 15.
D. Merino, N. Lalaoui, A. Morizot, P. Schneider, E. Solary, O. Micheau, Mol. Cell. Biol. 2006, 26, 7046-7055.
S. Shirley, A. Morizot, O. Micheau, Recent Pat. Anti-Cancer Drug Discovery 2011, 6, 311-323.
N. Chekkat, C. M. Lombardo, C. Seguin, M.-C. Lechner, F. Dufour, Y. Nominé, M. De Giorgi, B. Frisch, O. Micheau, G. Guichard, D. Altschuh, S. Fournel, Oncotarget 2018, 9, 15566.
K. Azijli, I. A. M. van Roosmalen, J. Smit, S. Pillai, M. Fukushima, S. de Jong, G. J. Peters, I. V. Bijnsdorp, F. A. E. Kruyt, Cancer Chemother. Pharmacol. 2014, 73, 1273-1283.
P. M. Nair, H. Flores, A. Gogineni, S. Marsters, D. A. Lawrence, R. F. Kelley, H. Ngu, M. Sagolla, L. Komuves, R. Bourgon, J. Settleman, A. Ashkenazi, Proc. Natl. Acad. Sci. USA 2015, 112, 5679-5684.
L. D. Mayer, A. S. Janoff, Mol. Interventions 2007, 7, 216-223.
L. Lebeau, S. Olland, P. Oudet, C. Mioskowski, Chem. Phys. Lipids 1992, 62, 93-103.
M. Kim, A. Pitchaiah, N.-J. Park, I. T. Hwang, K.-I. Lee, Lett. Org. Chem. 2012, 9, 628-631.
J. A. Heyes, D. Niculescu-Duvaz, R. G. Cooper, C. J. Springer, J. Med. Chem. 2002, 45, 99-114.
E. D. Goddard, N. J. Turro, P. L. Kuo, K. P. Ananthapadmanabhan, Langmuir 1985, 1, 352-355;
L. Piñeiro, M. Novo, W. Al-Soufi, Adv. Colloid Interface Sci. 2015, 215, 1-12.
B. C. Evans, C. E. Nelson, S. S. Yu, K. R. Beavers, A. J. Kim, H. Li, H. M. Nelson, T. D. Giorgio, C. L. Duvall, J. Vis. Exp. 2013, 73, e50166.